Nycomed & Merck fail to convince NICE about Daxas in COPD
This article was originally published in Scrip
Draft guidance from NICE is recommending that Nycomed and Merck provide evidence of how Daxas roflumilast performs in its likely clinical setting as an add-on to conventional therapies of chronic obstructive pulmonary disorder (COPD). NICE's appraisal committee says there is great uncertainty about the effect of roflumilast on reducing the rate of exacerbations as an add-on to triple or dual therapy for people with severe COPD. There was also some question of whether trials of roflumilast were conducted against appropriate comparators such as theophylline.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.